FDA approves Lilly's Cyramza; CEO Jimenez says more deals possible for Novartis; Merck testing human monoclonal antibody in outer space;

@FiercePharma: GlaxoSmithKline pledges $7.1B to add Novartis vaccines to its leading lineup. Story | Follow @FiercePharma

@TracyStaton: All of FiercePharma's Novartis-GSK-Lilly coverage in one place. Get it while it's hot. More | Follow @TracyStaton

@EricPFierce: FDA says import alert for saline from Baxter Canada plant tied to an importer trying to ship some to the U.S. Article | Follow @EricPFierce

@CarlyHFierce: So...who inherits Glaxo's cancer vaccine candidate? | Follow @CarlyHFierce

> The FDA has approved Eli Lilly's ($LLY) blockbuster hopeful, cancer med Cyramza. Story

> The Oklahoma Supreme Court has put a hold on the executions of two inmates it says have the right to challenge the secrecy around the drugs the state will use to put them to death. Story

> CEO Joe Jimenez says today's announced restructuring of Novartis' ($NVS) vaccine, animal health and consumer health businesses doesn't mean the Swiss drugmaker won't still be looking for some acquisitions to round out Novartis' three core operations. Story

> Taiho, the Japanese partner of Spanish pharmaceutical company Zeltia, will seek approval in Japan for their cancer drug Yondelis, which is already approved in 75 countries. Story  

> China's Shanghai Fosun Pharmaceutical Group and private equity firm TPG Capital have a deal to buy Chinese hospital operator Chindex International for about $461 million. Story

> India's Lupin has named Theresa Stevens, formerly of Astellas and Novartis ($NVS), as chief corporate development officer for its global operations. Release

Medical Device News

@FierceMedDev: Ulthera looks to $86M public offering for financial facelift. News | Follow @FierceMedDev

@VarunSaxena2: Updated with statement from Edwards: Federal court postpones Edwards' block of Medtronic's CoreValve. Story | Follow @VarunSaxena2

@EmilyWFierce: Bacterin International reports slight increase in Q1 revenues partly fueled by biologics growth. More | Follow @EmilyWFierce

@MichaelGFierce: Stanford researchers look at possible Trojan horse delivery. Story via the Stanford Daily | Follow @MichaelGFierce

> FDA deems recalled Covidien devices potentially deadly. Story

> Teleflex hit with FDA warning letter over respiratory devices. Item

Biotech News

@FierceBiotech: AbbVie heads to the FDA with its hep C combo in a race with Gilead, Merck. More | Follow @FierceBiotech

@JohnCFierce: GSK punts programs and rights on cancer to Novartis. MAGE-A3 a mess. Looks like they're done with cancer. Story | Follow @JohnCFierce

@DamianFierce: If I have past two days right: Valeant is buying Pfizer, which won an injunction against Medtronic, which is eyeing Allergan, and all are moving to Ireland. | Follow @DamianFierce

@EmilyMFierce: Experimental drug could thwart measles outbreaks. News | Follow @EmilyMFierce

> FDA OKs Lilly's blockbuster hopeful ramucirumab for stomach cancer. Story

> Analysts brace for a brawl as Valeant moves ahead with Allergan bid. Article

> VC groups put up $165M for a trifecta of biotech rounds. Roundup

Biotech Research News

> Researchers replicate controversial stem cell-cloning method. Story

> Experimental drug could thwart measles outbreaks. Piece

> Stabilizing protein complex in brain offers hope for Alzheimer's treatment. More

> Improved monitoring of zoonotic diseases could predict future Ebola outbreaks. Article

> Cancer stem cells responsible for treatment resistance, cancer relapse. News

> Mouse model could have predicted drug toxicity that killed 5 in clinical trial. Item

Pharma Manufacturing News

> Novartis deals with GSK and Lilly switch up manufacturing landscape. More

> FDA issued import alert after importer tried to ship saline not approved in U.S. Story

> GSK plans to unload site of closed Indian API plant. Article

> Cubist again recalls some Cubicin tied to contractor problem. Piece

> Hospira recalls 7 lots of propofol and one of lidocaine. News

> Novartis close on deal to sell contract patchmaker LTS Lohmann. Item

And Finally... Merck ($MRK) is trying to determine the physical structure of a human monoclonal antibody by crystallizing it in space aboard the SpaceX-3 cargo resupply mission launched April 14 to the International Space Station. Report

Suggested Articles

That didn’t take long. Sanofi CEO Paul Hudson has only been at the reins for a couple months, but on Tuesday, he unveiled a major shakeup.  

New "gold standard" data could further increase doctors' confidence in multiple myeloma med Darzalex, Johnson & Johnson says.

Could Monday's cancer buyout be a hint about what Sanofi CEO Paul Hudson will unveil at Tuesday's investor confab? Analysts think so.